Constellium Guides FY26 Adj EBITDA to $980M–$1.02B
CSTM has more than doubled off its 52-week low of $13.04.
Summary
Constellium issued FY26 adjusted EBITDA guidance of $980 million to $1.02 billion, and has now raised its full-year 2026 guidance following strong second quarter and first half 2026 results, which included record segment adjusted EBITDA. The midpoint of $1 billion compares to a Q1 2026 run-rate that showed adjusted EBITDA up 93% year-over-year, suggesting the company sees continued strength but not acceleration. The range provides a concrete benchmark for the Street to model against, and the stock's reaction will hinge on how this stacks up to consensus. With a $300 million buyback program already authorized and a major shareholder recently reducing its stake, the guidance adds a key piece to the investment puzzle.
Updates
· SEC 8-K — Q2 adjusted EBITDA was $439 million, net income $148 million, revenue $2.7 billion; FY26 adjusted EBITDA guidance raised to $980 million–$1.02 billion and free cash flow above $300 million.
At the time of this announcement, CSTM was trading at $30.04 on NYSE in the Manufacturing sector, with a market capitalization of approximately $4B. The 52-week trading range was $13.04 to $36.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.